Sociedad Americana de Hirudoterapia

A Wireless Near-Infrared Spectroscopy Device for Flap Monitoring: Proof of Concept in a Porcine Musculocutaneous Flap Model

Research article published in Journal of reconstructive microsurgery (2021)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Preclinical (animal)Desarrollo de fármacosWu C et al. · Journal of reconstructive microsurgery, 2021

Abstract

BACKGROUND:  Current near-infrared spectroscopy (NIRS)-based systems for continuous flap monitoring are highly sensitive for detecting malperfusion. However, the clinical utility and user experience are limited by the wired connection between the sensor and bedside console. This wire leads to instability of the flap-sensor interface and may cause false alarms. METHODS:  We present a novel wearable wireless NIRS sensor for continuous fasciocutaneous free flap monitoring. This waterproof silicone-encapsulated Bluetooth-enabled device contains two light-emitting diodes and two photodetectors in addition to a battery sufficient for 5 days of uninterrupted function. This novel device was compared with a ViOptix T.Ox monitor in a porcine rectus abdominus myocutaneous flap model of arterial and venous occlusions. RESULTS:  Devices were tested in four flaps using three animals. Both devices produced very similar tissue oxygen saturation (StO2) tracings throughout the vascular clamping events, with obvious and parallel changes occurring on arterial clamping, arterial release, venous clamping, and venous release. Small interdevice variations in absolute StO2 value readings and magnitude of change were observed. The normalized cross-correlation at zero lag describing correspondence between the novel NIRS and T.Ox devices was >0.99 in each trial. CONCLUSION:  The wireless NIRS flap monitor is capable of detecting StO2 changes resultant from arterial vascular occlusive events. In this porcine flap model, the functionality of this novel sensor closely mirrored that of the T.Ox wired platform. This device is waterproof, highly adhesive, skin conforming, and has sufficient battery life to function for 5 days. Clinical testing is necessary to determine if this wireless functionality translates into fewer false-positive alarms and a better user experience.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsFree Tissue FlapsMonitoring, PhysiologicMyocutaneous FlapOxygenSpectroscopy, Near-InfraredSwineVeins

Resumen

Current near-infrared spectroscopy (NIRS)-based systems for continuous flap monitoring are highly sensitive for detecting malperfusion.

Por qué esto importa para la hirudoterapia

Este estudio evaluó un novedoso sensor NIRS inalámbrico portátil para la monitorización continua de colgajos libres fasciocutáneos y lo comparó con un monitor cableado ViOptix T.Ox en un modelo porcino de colgajo miocutáneo de recto abdominal. Las pruebas realizadas en cuatro colgajos de tres animales mostraron que ambos dispositivos produjeron registros de saturación tisular de oxígeno muy similares durante los eventos de pinzamiento arterial y venoso, con una correlación cruzada normalizada superior a 0,99. Los autores concluyen que el dispositivo inalámbrico reflejó fielmente la plataforma cableada y señalan que se requieren pruebas clínicas para determinar si esto se traduce en una menor tasa de alarmas falsas positivas. Se trata de un estudio de un dispositivo en un modelo animal. El resumen no menciona sanguijuelas, hirudoterapia ni el secretoma de la sanguijuela, y no existe una conexión defendible con el ámbito de la ASH.

Citación

A Wireless Near-Infrared Spectroscopy Device for Flap Monitoring: Proof of Concept in a Porcine Musculocutaneous Flap Model

Wu C et al. · Journal of reconstructive microsurgery, 2021

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.